4D Molecular Therapeutics

Our Chief Financial & Business Officer, Uneek Mehra, and Chief Development Officer, Dhaval B. Desai, PharmD, shared insights on 4DMT’s clinical programs and explored the advancements shaping the future of #GeneticMedicines at the Jefferies London Healthcare Conference last week.   Our team enjoyed connecting with leaders and innovators across the global biotech and investment communities. Thank you to everyone who joined us for meaningful conversations.   #JefferiesHealthcare

Our management team will be at the Evercore ISI HealthCONx Conference in Coral Gables, FL, next week for 1x1 meetings and to present at a fireside chat. Register for our webcast here: https://lnkd.in/eMRz7gXa #HealthCONx2024 #Healthcare

We are thrilled to share that we have expanded our office at 5858 Horton, enabling us to foster greater collaboration, enhance our research capabilities and support our growing team as we ready for the launch of our global Phase 3 4FRONT program for 4D-150 in #wetAMD. This growth reflects our commitment to bold innovation and relentless execution as we continue to break boundaries and revolutionize #geneticmedicine for millions of patients in need.

Alpha-1 Antitrypsin Deficiency (Alpha-1 or A1AT) is a condition that affects around 200,000 individuals in the United States and Europe, yet significant unmet medical need remains despite existing therapies. Join us this #Alpha1AwarenessMonth to support this year’s theme, “The Power to Connect,” highlighting the importance of connecting with the Alpha-1 community, and advocating for those in need of a cure. Learn more here: https://lnkd.in/gKMhjiKp #Alpha1 #LungDisease

This week, Carlos Quezada Ruiz, M.D., FASRS, our SVP, Therapeutic Area Head, Ophthalmology, will be presenting at the Ophthalmology Innovation Summit in San Diego, CA. Join him to learn more about our potentially transformative #geneticmedicine approach to large market #ophthalmic diseases. Learn more: https://lnkd.in/eMRz7gXa Ophthalmology Innovation Source | #OISXIV #ophthalmology

We have expanded our Ophthalmology Advisory Board (OAB) with the appointments of Prof. Gemmy Cheung and Dr. Patricio Schlottmann. As we advance toward the launch of our global Phase 3 4FRONT program for 4D-150 in #wetAMD, the addition of these esteemed #retina specialists and thought leaders further strengthens our OAB. Their international expertise will be invaluable in guiding the successful execution of our Phase 3 4FRONT program. #ophthalmology Learn more about our OAB: https://lnkd.in/eheTEbYF

Our management team is looking forward to presenting at the Jefferies London #Healthcare Conference next week. Read the full details and register for our webcast here: https://lnkd.in/eMRz7gXa #JefferiesHealthcare

Today, we announced our third quarter financial results and provided operational highlights, including updates across our large market #ophthalmology portfolio and other pipeline programs.    Learn more about our recent progress and anticipated upcoming milestones heading into 2025: https://bit.ly/3O7XshH   #earnings 

We are thrilled to be named as a BioSpace 2025 Best Places to Work company 4 years running! A heartfelt thank you to our amazing team for making 4DMT not just a workplace, but a community. Our shared commitment to advancing innovative #GeneticMedicines drives us every day to break boundaries in order to improve patient lives. We are proud of the teamwork, dedication, ingenuity and diverse talents that our #4Deeps bring to the table each and every day.     View the full list here: https://lnkd.in/gKuFq2cG    #BestPlacesToWork

#WetAMD is a chronic disease, and many #patients require long-term, frequent injections directly into the eye.    We believe our #GeneticMedicine candidate, 4D-150, has the potential to address the treatment burden and progressive vision loss associated with wet AMD. Learn more: https://lnkd.in/ghisB4z5   #Ophthalmology